Kunstler: Warmonger's Remorse By James Howard Kunstler

New Post Public Reply Private Reply Replies (0) Message Board
SaltyMutt
162
Kunstler: Warmonger's Remorse

By James Howard Kunstler
April 13, 2018

I don’t know about you, but for a couple of days there I expected to wake up to the sight of mushroom clouds billowing across the horizon, all our exceptional hopes, wishes, troubles, and cares as a nation gone up in a vapor of smoking plastic. I think it was the Defense Secretary, nickname “Mad Dog,” who put the kibosh on the latest neocon temper tantrum against Bashar “The Animal” al-Assad. General Mattis told the House Armed Services Committee that the US was, er, “still looking for evidence” of an alleged poison gas attack against civilians in Douma, Syria.

That phrase “still looking for evidence” sounds like an elliptical way of saying we have no idea what, if anything, might have actually happened over there, just possibly even nothing at all. The Russians were busy looking for evidence on the ground in and around Douma, and they claimed to have found nothing — no traces of poison gas, no corpses, no gassing victims in the local hospital — and put out a call for international inspectors to come have a look. No reply on that from our side. Which does raise the question: are we even interested in the truth?

Maybe not. Also apparently not in the strange case of the poisoned Skripals that preceded the incident (or not) at Douma, and which touched off an expulsion orgy of Russian Diplomats among the US and our allies. Sergei Skripal, a Russian/British double-agent who had been exchanged to Britain in a spy-swap, fell ill along with his daughter, Yulia, on a park bench after lunching in quaint old Salisbury, Wiltshire, UK. The supposed weapon in that case, Novichok, an advanced neurotoxin that kills instantly, was found on the doorknob of the Skripal house, and yet the couple made it downtown, enjoyed a leisurely meal, and took a post-luncheon stroll. Casual observers did note that Salisbury is only a ten-minute drive from the UK’s Defence Science and Technology Laboratory, where military poisons are stored and evaluated, and after two weeks of idle chatter, scientists there released a galling report that they could not determine the origin of whatever knocked out the Skripals.

In any case, it didn’t kill them. Yulia Skripal was released from the hospital this week and is, apparently, some sort of hostage of the British government. You’d suppose that in a free country, Yulia might be interested in talking to the press, and certainly vice-versa, but she is incommunicado and was whisked away under guard to some mysterious hideaway. Sergei, we’re told, is coming out of it, too, in his hospital room, and seems to have nothing to say, either. There was chatter in the US media that the Skripals might be sent here under some sort of US witness protection program. It looks like the US and Britain are running out of rugs to sweep stuff under.

Clownish as it was, the Skripal affair ramped up already poor relations between Russia and the West (mainly the US) to code red levels, as perhaps intended by the dream factory known as the Intelligence Community. At least that’s how it played in Deep State officialdom. The distracted public has stopped paying attention to it. Note: neither The New York Times, the WashPo, nor CNN, have issued any righteous calls for answers in the malodorous Skripal matter. They’re all probably embarrassed that they latched on to the story and played it like “Pearl Harbor.” But no one is accountable and the net result is a Russian diplomatic presence reduced to a skeleton crew in Washington, which can’t be a great thing for mutual understanding.

So, now, the Russians and Syrians have had plenty of time to scramble their airplanes and move personnel around the landscape to await another US smackdown, and the Russians have promised to shoot down our missiles with some spooky new technology, and it looks like our side is blinking. Do we have any idea whether the Russians actually can shoot down our offensive missiles? Maybe we don’t want to know. We surely don’t want the world to know. It would be — how you say? — bad optics.

Of course, this latest uproar over the Douma poison gas incident coincided with the first day at work of National Security Advisor John Bolton, a reputed devotee of military monkey business. But it’s possible that even Mr. Bolton is embarrassed by these crude shenanigans, which just preceded his return to influence on the political scene. If he has any influence at all, perhaps he might use it to suggest that the President of the United States just shut the fuck up for a while.

Support this website by visiting Jim’s Patreon Page! https://tinyurl.com/ycozs4rm ;

http://kunstler.com/clusterfuck-nation/warmongers-remorse/ ;
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 4

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 7

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 4

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 4

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading

Top 5 Most Recently Viewed Articles

Vaccinex Unveils Efficacy Insights for Pepinemab in Alzheimer’s Study

Updated Category News Views 71

Vaccinex Provides Update on Pepinemab Study for Alzheimer’s Disease ROCHESTER, N.Y. — Vaccinex, Inc. (NASDAQ: VCNX), a forward-thinking biotechnology firm, is making significant strides in the treatment of Alzheimer's disease (AD) and cancer. The company is focused on a unique approach through the inhibition of Semaphorin 4D (SEMA4D). Recently, it was announced that...

Continue Reading
Legal Inquiry into Netflix, Inc. (NFLX) Attracts Investor Attention

Updated Category News Views 287

Understanding the Investigation into Netflix, Inc. Recently, the law firm Robbins Geller Rudman & Dowd LLP has initiated a formal investigation into Netflix, Inc. (NASDAQ: NFLX). This inquiry primarily focuses on potential violations of U.S. federal securities laws that may have occurred within the company. The Implications for Investors This investigation comes at a...

Continue Reading
Norway's Wealth Fund Expands Portfolio with London Investment

Updated Category News Views 221

Norway's Sovereign Wealth Fund Takes Bold Step in London Norway's sovereign wealth fund, expertly managed by Norges Bank Investment Management, has recently made headlines with its strategic acquisition of a 25% stake in a notable portfolio of office and retail properties located in London's prestigious Mayfair district. Significant Investment in a Prime Location This...

Continue Reading
Exagen Inc. Announces New Biomarkers and Financial Success

Updated Category News Views 291

Exagen Inc. Introduces Groundbreaking Biomarkers for Autoimmune Diseases Innovative testing aims to enhance patient diagnosis and care Exagen Inc. (Nasdaq: XGN), a pioneering company in autoimmune testing, has achieved a significant milestone by receiving conditional approval from the New York State Department of Health for its advanced assays to diagnose systemic lupus...

Continue Reading
Pacaso's Financial Growth in 2025: A Closer Look At Results

Updated Category News Views 1306

Pacaso Shows Promising First Half Financial Performance Pacaso, the innovative platform for co-owned luxury vacation homes, has recently shared its financial results for the first half of 2025, demonstrating strong stability and improved efficiency despite a challenging broader housing market. The company reported an impressive adjusted gross profit while managing to...

Continue Reading